Trials / Unknown
UnknownNCT02880800
Does IVPCA Increase Opioid Consumption and Side Effects in Fast Track Orthopedic Procedures?
Does the Use of Intravenous Patient Controlled Analgesia (IVPCA) Increase Opioid Consumption and Side Effects in Fast Track Orthopedic Procedures?
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Mount Sinai Hospital, Canada · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The study aims to compare the use of intravenous patient controlled analgesia (IVPCA) versus the delivery of pain relief (per oral and intravenous (IV) medications as rescues analgesia) on an as needed basis within a well defined fast track protocol that includes multimodal analgesia for patients who are undergoing elective primary knee replacement surgery. The investigators assumed that with the multimodal analgesia regimen without the use of IVPCA will demonstrate decreased consumption of postoperative opioids, reduced incidence of opioids related side effects and decreased length of stay in the hospital.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Morphine as IVPCA | Morphine as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of morphine as below: Morphine bolus 1mg with a lockout interval of 5 minutes, no background infusion and maximum 30 mg in 4 hours |
| DRUG | Hydromorphone as IVPCA | Hydromorphone as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of Hydromorphone as below: Hydromorphone bolus 0.2 mg with a lockout interval of 5 minutes and a maximum dose of 6 mg in 4 hours. |
| DRUG | Morphine | IV opioids: Morphine 2 to 5 mg every 1h PRN (max. 20 mg/4h) |
| DRUG | Hydromorphone | Hydromorphone 0.5 - 1 mg every 1h PRN (max. 4 mg/4h) |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2017-08-01
- Completion
- 2017-08-01
- First posted
- 2016-08-26
- Last updated
- 2016-08-26
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02880800. Inclusion in this directory is not an endorsement.